Tags

Type your tag names separated by a space and hit enter

Peroxisome proliferator-activated receptor-delta agonist enhances vasculogenesis by regulating endothelial progenitor cells through genomic and nongenomic activations of the phosphatidylinositol 3-kinase/Akt pathway.
Circulation. 2008 Sep 02; 118(10):1021-33.Circ

Abstract

BACKGROUND

Despite the therapeutic potential of endothelial progenitor cells (EPCs) in ischemic vascular diseases, their insufficient numbers limit clinical applications. Peroxisome proliferator-activated receptor (PPAR)-delta belongs to the nuclear hormone receptor superfamily, and its functions in various tissues and cells are almost unexplored, especially with respect to vascular biology.

METHODS AND RESULTS

PPAR-delta activation in EPCs phosphorylated Akt, and this phosphorylation was mediated not only by genomic but also by nongenomic pathways through interaction with the regulatory subunit of phosphatidylinositol 3-kinase. PPAR-delta activation with agonist (GW501516 or L-165041) increased the proliferation of human EPCs and protected them from hypoxia-induced apoptosis. In addition, PPAR-delta activation enhanced EPC functions, such as transendothelial migration, and tube formation. These actions by PPAR-delta activation in EPCs were dependent on the phosphatidylinositol 3-kinase/Akt pathway. In ischemic hindlimb of mice models, transplantation of PPAR-delta agonist-treated human or mouse EPCs enhanced blood flow recovery to ischemic limbs compared with vehicle-treated EPCs. In EPCs from PPAR-delta-knockout mice, however, treatment with PPAR-delta agonist did not enhance in vivo vasculogenic potential. Systemic administration of PPAR-delta agonist increased hematopoietic stem cells in bone marrow and EPCs in peripheral blood, leading to improved vasculogenesis with incorporation of bone marrow-derived cells to new vessels in a corneal neovascularization model and limb salvage with better blood flow in an ischemic hindlimb model.

CONCLUSIONS

The results of our study suggest that PPAR-delta agonist has therapeutic vasculogenic potential for the treatment of ischemic cardiovascular diseases.

Authors+Show Affiliations

Cardiovascular Center, Seoul National University Hospital, 28 Yongon-dong Chongno-gu, Seoul 110-744, Korea.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18711014

Citation

Han, Jung-Kyu, et al. "Peroxisome Proliferator-activated Receptor-delta Agonist Enhances Vasculogenesis By Regulating Endothelial Progenitor Cells Through Genomic and Nongenomic Activations of the Phosphatidylinositol 3-kinase/Akt Pathway." Circulation, vol. 118, no. 10, 2008, pp. 1021-33.
Han JK, Lee HS, Yang HM, et al. Peroxisome proliferator-activated receptor-delta agonist enhances vasculogenesis by regulating endothelial progenitor cells through genomic and nongenomic activations of the phosphatidylinositol 3-kinase/Akt pathway. Circulation. 2008;118(10):1021-33.
Han, J. K., Lee, H. S., Yang, H. M., Hur, J., Jun, S. I., Kim, J. Y., Cho, C. H., Koh, G. Y., Peters, J. M., Park, K. W., Cho, H. J., Lee, H. Y., Kang, H. J., Oh, B. H., Park, Y. B., & Kim, H. S. (2008). Peroxisome proliferator-activated receptor-delta agonist enhances vasculogenesis by regulating endothelial progenitor cells through genomic and nongenomic activations of the phosphatidylinositol 3-kinase/Akt pathway. Circulation, 118(10), 1021-33. https://doi.org/10.1161/CIRCULATIONAHA.108.777169
Han JK, et al. Peroxisome Proliferator-activated Receptor-delta Agonist Enhances Vasculogenesis By Regulating Endothelial Progenitor Cells Through Genomic and Nongenomic Activations of the Phosphatidylinositol 3-kinase/Akt Pathway. Circulation. 2008 Sep 2;118(10):1021-33. PubMed PMID: 18711014.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Peroxisome proliferator-activated receptor-delta agonist enhances vasculogenesis by regulating endothelial progenitor cells through genomic and nongenomic activations of the phosphatidylinositol 3-kinase/Akt pathway. AU - Han,Jung-Kyu, AU - Lee,Hyun-Sook, AU - Yang,Han-Mo, AU - Hur,Jin, AU - Jun,Soo-In, AU - Kim,Ju-Young, AU - Cho,Chung-Hyun, AU - Koh,Gou-Young, AU - Peters,Jeffrey M, AU - Park,Kyung-Woo, AU - Cho,Hyun-Jai, AU - Lee,Hae-Young, AU - Kang,Hyun-Jae, AU - Oh,Byung-Hee, AU - Park,Young-Bae, AU - Kim,Hyo-Soo, Y1 - 2008/08/18/ PY - 2008/8/20/pubmed PY - 2008/9/24/medline PY - 2008/8/20/entrez SP - 1021 EP - 33 JF - Circulation JO - Circulation VL - 118 IS - 10 N2 - BACKGROUND: Despite the therapeutic potential of endothelial progenitor cells (EPCs) in ischemic vascular diseases, their insufficient numbers limit clinical applications. Peroxisome proliferator-activated receptor (PPAR)-delta belongs to the nuclear hormone receptor superfamily, and its functions in various tissues and cells are almost unexplored, especially with respect to vascular biology. METHODS AND RESULTS: PPAR-delta activation in EPCs phosphorylated Akt, and this phosphorylation was mediated not only by genomic but also by nongenomic pathways through interaction with the regulatory subunit of phosphatidylinositol 3-kinase. PPAR-delta activation with agonist (GW501516 or L-165041) increased the proliferation of human EPCs and protected them from hypoxia-induced apoptosis. In addition, PPAR-delta activation enhanced EPC functions, such as transendothelial migration, and tube formation. These actions by PPAR-delta activation in EPCs were dependent on the phosphatidylinositol 3-kinase/Akt pathway. In ischemic hindlimb of mice models, transplantation of PPAR-delta agonist-treated human or mouse EPCs enhanced blood flow recovery to ischemic limbs compared with vehicle-treated EPCs. In EPCs from PPAR-delta-knockout mice, however, treatment with PPAR-delta agonist did not enhance in vivo vasculogenic potential. Systemic administration of PPAR-delta agonist increased hematopoietic stem cells in bone marrow and EPCs in peripheral blood, leading to improved vasculogenesis with incorporation of bone marrow-derived cells to new vessels in a corneal neovascularization model and limb salvage with better blood flow in an ischemic hindlimb model. CONCLUSIONS: The results of our study suggest that PPAR-delta agonist has therapeutic vasculogenic potential for the treatment of ischemic cardiovascular diseases. SN - 1524-4539 UR - https://www.unboundmedicine.com/medline/citation/18711014/Peroxisome_proliferator_activated_receptor_delta_agonist_enhances_vasculogenesis_by_regulating_endothelial_progenitor_cells_through_genomic_and_nongenomic_activations_of_the_phosphatidylinositol_3_kinase/Akt_pathway_ L2 - https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.108.777169?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -